BOCA RATON, Fla., Nov. 8 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) (the "Company") announced that, at
today's Special Meeting of Stockholders, its stockholders voted
overwhelmingly to approve the previously announced sale of assets
transaction involving Biotest Pharmaceuticals Corporation and Biotest AG.
More than 60 percent of the outstanding shares of the Company's common
stock were represented at the meeting and 98 percent of those shares were
voted in favor of the sale of assets transaction.
"We are pleased and gratified by the strong support we have received
from our stockholders and thank them for their continued commitment to Nabi
Biopharmaceuticals," said Leslie Hudson, Ph.D., the Company's interim
president and chief executive officer.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and, in certain areas, market
products that target serious medical conditions in the areas of hepatitis
and transplants, gram positive bacterial infections and nicotine addiction.
We are a vertically integrated company with sales of antibodies and other
biologics, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], a
pipeline of products in various stages of development and a
state-of-the-art manufacturing capability. The company operates through two
strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi
Biologics has responsibility for the company's protein and immunological
products and development pipeline, including Nabi- HB. Nabi Pharmaceuticals
is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and
StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine)
development programs. For a complete list of pipeline products, please go
to: http://www.nabi.com/pipeline/index.php. In September 2007, Nabi
announced that it had entered into a definitive agreement with Biotest AG
to sell the Nabi Biologics strategic business unit to Biotest
Pharmaceuticals Corporation, including Nabi-HB(R) [Hepatitis B Immune
Globulin (Human)], and other plasma business assets, including Nabi's
state-of-the-art plasma protein production plant, and nine FDA-certified
plasma collection centers across the U.S. The acquisition also will include
certain of Nabi's Corporate Shared Services group assets and the company's
Boca Raton, Florida headquarters and other facilities, as well as the
assumption of certain liabilities, and is expected to close by the end of
the year. The company is headquartered in Boca Raton, Florida. For
additional information about Nabi Biopharmaceuticals, please visit our Web
site: http://www.nabi.com.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php
CONTACT:
Nabi Biopharmaceuticals Investor Relations,
+1-301-770-3099
|
